New cancer drug NX-1607 enters first human trials
NCT ID NCT05107674
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This early-stage trial tests a new drug called NX-1607 in 345 adults with advanced cancers like ovarian, lung, and melanoma. The goal is to check safety and find the right dose. Participants have cancers that have not responded to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrookes Cambridge University Hospital
RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
Beatson West of Scotland Cancer Centre
RECRUITINGGlasgow, G12 0YN, United Kingdom
Contact Email: •••••@•••••
Contact
-
Churchill Hospital
COMPLETEDOxford, OX3 7LE, United Kingdom
-
City of Hope
COMPLETEDDuarte, California, 91010, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
Northern Centre for Cancer Care
RECRUITINGNewcastle, NE7 7DN, United Kingdom
-
Royal Marsden Hospital NHS Foundation Trust
RECRUITINGSutton, Surrey, SM2 5PT, United Kingdom
-
Sarah Cannon Research Institute
RECRUITINGLondon, W1G 6AD, United Kingdom
Contact Email: •••••@•••••
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
Contact Email: •••••@•••••
Contact
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
Contact Email: •••••@•••••
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
-
University of Colorado School of Medicine
RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
Contact
Contact
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••
Contact
-
University of Southern California
RECRUITINGLos Angeles, California, 90007, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NX-1607 (a CBL-B inhibitor) and paclitaxel
What this could lead to
If successful, this could point toward a new treatment option for several advanced cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. It is small and focused on safety, not on proving it works.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.